Patent Settlement

Automatically clustered newsroom coverage around one of the most active themes in the intellectual property ecosystem.

PatentsUSA

Zydus Lifesciences Reaches $120 Million Patent Settlement with Astellas Over Mirabegron in US Market

Zydus Lifesciences and its US subsidiary have finalized a patent dispute settlement with Astellas Pharma concerning the US rights to Mirabegron, marketed as Myrbetriq by Astellas. Under the terms, Zydus will pay $120 million upfront plus a per-unit royalty on generic sales through September 2027, allowing uninterrupte…

Thursday, May 14, 2026

Newsletters & Digests

Follow Patent Settlement

Subscribe to receive daily and weekly newsroom coverage aligned to this trend cluster and adjacent IP developments.

Explore

All newsroom coverage Filtered archive